

Form PTO-1449
(Rev. 7-80)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.
RR-371 PCT/US CIP

Serial No.
09/855,176

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AUG 20 2001

Applicant

Edward E. Knaus, et. al.

Filing Date

May 14, 2001

Group

1642

AUG 23 2001

RECEIVED
TECH CENTER 1600
2900

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date <input checked="" type="checkbox"/> Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation
						Yes No

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

RS	✓	Kumar, R. et al, "Synthesis of Brain-Targeted 5-Iodo-, 5-Vinyl and (E)-5 (2-Iodovinyl)-2'-deoxyuridines Coupled to a Dihydropyridine = Pyridinium Salt Redox Chemical Delivery System", <u>J. Heterocycl. Chem.</u> , Vol 28, No. 3 pp. 711-715 (Apr-May 1991).
		Balzarini, J. et al, "Thymidylate Synthase Is the Principal Target Enzyme for the Cytostatic Activity of (E)-5-(2-Bromovinyl)-2'-deoxyuridine Against Murine Mammary Carcinoma (FM3A) Cells Transformed with the Herpes Simplex Virus Type 1 or Type 2 Thymidine Kinase Gene", <u>Mol. Pharmacol.</u> , Vol. 32, No. 3, pp. 410-416 (September 1987).
RS	✓	Balzarini, J. et al, "Comparative Cytostatic Activity for Different Anti-herpetic Drugs against Herpes Simplex Virus Thymidine Kinase Gene-Transfected Tumor Cells", <u>Mol. Pharmacol.</u> , Vol. 45, No. 6, pp. 1253-1258 (June 1994).

EXAMINER

RE

DATE CONSIDERED

11/7/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449
(Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
RR-371 PCT/US CIPSerial No.
09/855,176

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AUG 20 2001

Applicant
Edward E. Knaus et.al.Filing Date
May 14, 2001Group
1642

AUG 29 2001

TECH CENTER 1000/2000

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DS		Balzarini, J. et al, "Highly Selective Cytostatic Activity of (E)-5-(2-Bromovinyl)-2'-deoxyuridine Derivatives for Murine Mammary Carcinoma (FM3A) Cells Transformed with the Herpes Simplex Virus Type 1 Thymidine Kinase Gene", <u>Mol. Pharmacol.</u> , Vol. 28, No. 6, pp. 581-587 (December 1985).
1		Dougan H. et al, "No-Carrier-Added 1-beta-D Arabinofuranosyl- 5E -2-Radioiodovinyl Uracil (IVARAU) Probes for the Detection of Herpes Simplex Virus-Specified Thymidine Kinase <u>in vivo</u> and <u>in vitro</u> ", <u>J. Nucl. Med.</u> , Vol. 34, No. 5 Suppl., p. 235P (June 1993).
		Gill, M.J. et al, "Quantitative Uptake Studies of ¹³¹ I-Labeled (E)-5-(2-Iodovinyl)-2'-Deoxyuridine in Herpes Simplex Virus-Infected Cells <u>In Vitro</u> ", <u>Antimicrob. Agents Chemother.</u> , Vol. 25, No. 4, pp. 476-478 (April 1984).
DS		Morin, K.W. et al, "Synthesis of brain-targeted 1-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)-(E)-5-(2-iodovinyl)uracil coupled to a dihydropyridine =

EXAMINER

DR. CO

DATE CONSIDERED


1/17/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTC-1449
(Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
RR-371 PCT/US CIPSerial No.
09/855,176

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



AUG 20 2001

Applicant

Edward E. Knaus et.al.

Filing Date

May 14, 2001

Group

1642

RECEIVED

AUG 23 2001

TECH CENTER 1600/RS CO

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation		
					Yes		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		pyridinium salt redox chemical-delivery system", <u>Carbohydrate Research</u> ,
		Vol. 249, No. 1, pp. 109-116 (October 18th, 1993).
<i>RS</i>		Robins, M.J. et al, "Nucleic Acid Related Compounds. 65. New Syntheses of
		1-(beta-D-Arabinofuranosyl)-5(E)-(2-iodovinyl)uracil (IV Ara U) from
		Vinylsilane Precursors. Radioiodine Uptake as a Marker for Thymidine
		Kinase Positive Herpes Viral Infections", <u>J. Med. Chem.</u> , Vol. 34, No. 7,
		pp. 2275-2280 (July 1991).
		Yokota, T. et al, "Incorporation of (E)-5-(2-Iodovinyl)-2'-Deoxyuridine into
		Deoxyribonucleic Acids of Varicella-Zoster Virus (TK+ and TK- Strains) -
		Infected Cells" <u>Mol. Pharmacol.</u> , Vol. 31, No. 5, pp. 493-499 (May 1987).
<i>R</i>		De Clercq, E. et al, "Metabolism of the Carbocyclic Analogue of (E)-5-(2-
		Iodovinyl)-2'-deoxyuridine in Herpes Simplex Virus-infected Cells", <u>J.</u>
		<u>Biol. Chem.</u> , Vol. 260, No. 19, pp. 10621-10628 (September 5, 1985).

EXAMINER

[Signature]

DATE CONSIDERED

11/6/03

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449
(Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
RR-371 PCT/US CIPSerial No.
09/855,176

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AUG 20 2001

Applicant
Edward E. Knaus et.al.Filing Date
May 14, 2001

RECEIVED

AUG 23 2001

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation
						Yes

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

T3	Ram, Z. et al, "The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats", <u>J. Neurosurg.</u> , Vol. 81, No. 2, pp. 256-260 (August, 1994).
	Ohno, T. et al, "Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial Injury", <u>Science</u> , Vo. 265, pp. 781-784 (5 August 1994).
	Short, M.P. et al, "Gene Delivery to Glioma Cells in Rat Brain by Grafting of a Retrovirus Packaging Cell Line", <u>J. Neuroscience Res.</u> , Vol 27, pp. 427-439 (1990).
	Takamiya, Y. et al, "An experimental model of retrovirus gene therapy for malignant brain tumors", <u>J. Neurosurg.</u> , Vol. 79, pp. 104-110 (July, 1993).
T5	Culver, K.W. et al, "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors", <u>Science</u> , Vol. 256, pp. 1550-1552 (12 June 1992).

EXAMINER

Melvin


DATE CONSIDERED

167/93

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Rev. 7-80)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. RR-371 PCT/US CIP	Serial No. 09/855,176
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				Applicant Edward E. Knaus et.al.	
		Filing Date May 14, 2001	Group 1642		
U.S. PATENT DOCUMENTS					
Examiner Initial		Document Number	Date	Name	Class Subclass Filing Date if Appropriate
<i>RECEIVED</i>					
AUG 23 2001					
TECH CENTER 1600/2000					
FOREIGN PATENT DOCUMENTS					
	Document Number	Date	Country	Class	Subclass Translation Yes No
<i>RECEIVED</i>					
AUG 23 2001					
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
<p><i>TB</i></p> <p>Oldfield, E.H. et al, "Protocol Guide for Patient Referrals, Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with the Thymidine Kinase Gene and Intravenous Ganciclovir 92-N-0246", <u>Hum. Gene Ther.</u>, Vol. 4, pp. 60-69 (1993).</p>					
<p>Freeman, S.M. et al, "Treatment of Ovarian Cancer Using HSV-IIC Gene Modified Vaccine - Regulatory Issues", <u>Hum. Gene Ther.</u>, Vol. 3, pp. 342-346 (1992)</p>					
<p>Moolten, F.L. et al, "Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transferred by Retroviral Vectors", <u>J. National Cancer Institute</u>, Vol. 82, No. 4, pp. 297-300 (February 21, 1990).</p>					
<p>Freeman, S.M. et al, "The 'Bystander Effect': Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified", <u>Cancer Research</u>, Vol. 53, pp. 5274-5283 (1993).</p>					
<p><i>PS</i></p> <p>Barba, D. et al, "Development of anti-tumor immunity following thymidine kinase-mediated killings of experimental brain tumors", <u>Proc. Natl., Acad.</u></p>					
EXAMINER <i>[Signature]</i>		DATE CONSIDERED <i>1/7/03</i>			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Form PTO-1449 (Rev. 7-80)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. RR-371 PCT/US CIP	Serial No. 09/855,176		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) AUG 20 2001		Applicant Edward E. Knaus et.al.					
		Filing Date May 14, 2001	Group 1642				
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date Appropriate
RECEIVED							
AUG 23 2001							
TECH CENTER 1600/2000							
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes
							No
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
RS							
Sci. USA, Vol. 91, pp. 4348-4352 (May 1994).							
Hasegawa, Y. et al, "Gene Transfer of Herpes Simplex Virus Type I Thymidine Kinase Gene as a Drug Sensitivity Gene into Human Lung Cancer Cell Lines Using Retroviral Vectors", Am. J. Resp. Cell and Mol. Biol., Vol. 8, pp. 655-661 (1993).							
Manome, Y. et al, "Enhancer Sequence of the DF3 Gene Regulate Expression of the Herpes Simplex Virus Thymidine Kinase Gene and Confer Sensitivity of Human Breast Cancer Cells to Ganciclovir", Cancer Research, Vol. 54, pp. 5408-5413 (October 15, 1994).							
B							
Smythe, W.R. et al, "Use of Recombinant Adenovirus to Transfer the Herpes Simplex Virus Thymidine Kinase (HSVtk) Gene to Thoracic Neoplasms: An Effective <u>in Vitro</u> Drug Sensitization System", Cancer Research, Vol. 54, pp. 2055-2059 (April 15, 1994).							
EXAMINER <i>W.L.C.</i>		DATE CONSIDERED <i>1/7/03</i>					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 (Rev. 7-80)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. RR-371 PCT/US CIP	Serial No. 09/855,176
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				Applicant Edward E. Knaus et.al.	
		Filing Date May 14, 2001	Group 1642		
U.S. PATENT DOCUMENTS					
Examiner Initial		Document Number	Date	Name	Class Subclass Filing Date if Appropriate
RECEIVED					
AUG 23 2001					
TECH CENTER 1600/2900					
FOREIGN PATENT DOCUMENTS					
	Document Number	Date	Country	Class	Subclass Translation
					Yes No
OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)					
 	Vile, R.G. et al, "In Vitro and in Vivo Targeting of Gene Expression to Melanoma Cells", <u>Cancer Research</u> , Vol. 53, pp. 962-967 (March 1, 1993).				
	Mercer, J.R. et al, "Synthesis and Tumor Uptake of 5-Halo-1-(2'-fluoro-2'-deoxybeta-D-ribofuranosyl) [2- ¹⁴ C] uracils", <u>J. Med. Chem.</u> , Vol. 30, No. 4, pp. 670-675 (1987).				
	Lopez, C. et al, "2'-Fluoro-5-Iodo-Aracytosine, a Potent and Selective Anti-Herpesvirus Agent", <u>Antimicrob. Agents Chemother.</u> , Vol. 17, No. 5, pp. 803-806 (May 1980).				
	Coderre, J.A. et al, "Mechanism of Action of 2',5-Difluoro-1-arabinosyluracil", <u>J. Med. Chem.</u> , Vol. 26, No. 8, pp. 1149-1152 (1983).				
	Ayisi, N.K. et al, "Comparative Metabolism of E-5-(2-Bromovinyl)-2'-deoxyuridine and 1-beta-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil in Herpes Simplex Virus-Infected Cells", <u>Molecular Pharmacology</u> , Vol. 31, pp. 422-429 (1987).				
EXAMINER 		DATE CONSIDERED <i>1/7/03</i>			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Form PTO-1449
(Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
RR-371 PCT/US CIPSerial No.
09/855,176

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AUG 20 2001

Applicant Edward E. Knaus et al

Filing Date
May 14, 2001Group
1642

RECEIVED

AUG 23 2001

TECH CENTER 1600/250

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

PS		Chou, T. et al, "Synthesis and Biological Effects of 2'-Fluoro-5-Ethyl-1-beta-D-Arabinofuranosyluracil", <u>Antimicrob. Agents Chemother.</u> , Vol. 31, No. 9, pp. 1355-1358 (September 1987).					
		Bodor, N. et al, "Site-Specific, Sustained Release of Drugs to the Brain", <u>Science</u> , Vol. 214, pp. 1370-1372 (18 December 1981).					
		Littler, E. et al, "Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir", <u>Nature</u> , Vol. 358, pp. 160-161 (9 July 1992).					
		Sullivan, V. et al, "A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells", <u>Nature</u> , Vol 358, pp. 162-164 (9 July 1992).					
RS		Morin, K.W. et al, "Brain-Directed Design Synthesis and Biological Evaluation of a Radioactive Probe for Scintigraphic Detection of HSV-1 Thymidine Kinase", <u>Clinical Nuclear Medicine</u> , Vol. 19, No. 10, page 934 (October 1994).					

EXAMINER

Miller

DATE CONSIDERED

1/16/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Fórm PTO-1449
(Rev. 7-80)

**U.S. Department of Commerce
Patent and Trademark Office**

Atty. Docket No.

Serial No.
09/855.176

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AUG 20 2001

Applicant

Filing Date
May 14, 2001

RECEIVED

AUG 23 2001

U.S. PATENT DOCUMENTS

~~TECH CENTER 1600/2900~~

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)

PS

Balzarini J. et al, "Novel (E)-5-(2-iodovinyl)-2'-deoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors," Gene Therapy Vol. 2, pp. 317-322 (February, 1995).

Wiebe, L.I. et al, "HSV-Thymidine Kinase: a molecular target for transfection imaging in gene therapy of cancer," Antiviral Research, Volume 26/3 p.A30, No. 152 (March, 1995).

Morin, K.W. et al, "Metabolic Imaging in Gene Therapy of Cancer," European Journal of Nuclear Medicine Vol. 21, No. 10 (Suppl.) p. S125, No. 489 (1994).

PS

Ross, B.D. et al, "Assessment of ganciclovir toxicity to experimental intracranial gliomas following recombinant adenoviral-mediated transfer of the herpes simplex virus thymidine kinase gene by magnetic resonance imaging and proton magnetic resonance spectroscopy," Clin. Cancer Res. (1995), 1(6) pp. 651-7.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449
(Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
RR-371 PCT/US CIPSerial No.
09/855,176INFORMATION DISCLOSURE CITATION
O I P E
(Use several sheets if necessary)AUG 20 2001
2001Applicant
Edward E. Knaus et.al.Filing Date
May 14, 2001Group
1642

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

TS
RS

Ram, Z. et al, "Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors," J. Neurosurg. (1993), 79(3) pp. 400-7.

Elmaleh, David R. et al, "Technetium-99m-labeled nucleotides as tumor seeking radiodiagnostic agents," Proc. Natl. Acad. Sci. U.S.A. (1984), 81(3), pp. 918-21.

TG

PCT International Application No. PCT/US96/03553 filed March 14, 1996 and published September 16, 1996 by Blasberg et al, entitled "Non-Invasive Imaging of Gene Transfer."

EXAMINER

W.C.

DATE CONSIDERED

11/7/03

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.